問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Thoracic Medicine

MacKay Memorial Hospital

Division of Thoracic Medicine

更新時間：2023-09-19

楊勝雄
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊勝雄

List

29Cases

2025-09-01 - 2035-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Subcutaneous injections

Participate Sites
6Sites

Recruiting6Sites

2025-09-30 - 2033-12-31

Phase II

Not yet recruiting
A Study of V940/​Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (INTerpath-13)

  • Condition/Disease

    Squamous Non-small Cell Lung Cancer

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2023-12-01 - 2031-05-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    注射劑 注射劑

Participate Sites
11Sites

Recruiting11Sites

2023-11-15 - 2031-12-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    MK-2870PemetrexedDocetaxel

Participate Sites
12Sites

Not yet recruiting9Sites

Recruiting3Sites

2024-05-01 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2024-04-15 - 2033-12-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting11Sites

Recruiting1Sites

2021-03-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-09-01 - 2038-12-31

Phase III

Active
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

  • Condition/Disease

    NSCLC

  • Test Drug

    injection

Participate Sites
9Sites

Recruiting9Sites

2019-05-01 - 2026-12-31

Phase III

Active
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer

  • Condition/Disease

    Metastatic Nonsquamous Non-Small-Cell Lung Cancer

  • Test Drug

    KEYTRUDA/ Lynparza

Participate Sites
6Sites

Recruiting6Sites

2021-03-01 - 2028-08-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB